These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 31676575)
1. Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Zhou J; Liu Y; Zhang Y; Li Q; Cao Y Cancer Res; 2020 Feb; 80(3):591-601. PubMed ID: 31676575 [TBL] [Abstract][Full Text] [Related]
2. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
3. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833 [TBL] [Abstract][Full Text] [Related]
4. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157 [TBL] [Abstract][Full Text] [Related]
5. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Suzuki C; Blomqvist L; Sundin A; Jacobsson H; Byström P; Berglund Å; Nygren P; Glimelius B Ann Oncol; 2012 Apr; 23(4):948-54. PubMed ID: 21832285 [TBL] [Abstract][Full Text] [Related]
6. Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). Liu L; Erickson NT; Ricard I; von Weikersthal LF; Lerch MM; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Link H; Höffkes HG; Moehler M; Gesenhues AB; Theurich S; Michl M; Modest DP; Algül H; Stintzing S; Heinemann V; Holch JW Int J Cancer; 2022 Jan; 150(1):112-123. PubMed ID: 34431518 [TBL] [Abstract][Full Text] [Related]
7. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey. Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status. Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990 [TBL] [Abstract][Full Text] [Related]
10. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Giessen C; Laubender RP; Fischer von Weikersthal L; Schalhorn A; Modest DP; Stintzing S; Haas M; Mansmann UR; Heinemann V Cancer Sci; 2013 Jun; 104(6):718-24. PubMed ID: 23480146 [TBL] [Abstract][Full Text] [Related]
11. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634 [TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465 [TBL] [Abstract][Full Text] [Related]
13. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey A; Hedrick EE; Mass RD; Sarkar S; Suzuki S; Ramanathan RK; Hurwitz HI; Goldberg RM; Sargent DJ J Clin Oncol; 2008 Jan; 26(2):183-9. PubMed ID: 18182660 [TBL] [Abstract][Full Text] [Related]
14. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462 [TBL] [Abstract][Full Text] [Related]
15. Negative Hyperselection of Patients With Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295 [TBL] [Abstract][Full Text] [Related]
16. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tian Y; Sidhu R Ann Oncol; 2014 Jan; 25(1):107-16. PubMed ID: 24356622 [TBL] [Abstract][Full Text] [Related]
17. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Taieb J; Geissler M; Rivera F; Karthaus M; Wilson R; Loupakis F; Price T; Tracy M; Burdon P; Peeters M Clin Colorectal Cancer; 2019 Dec; 18(4):245-256.e5. PubMed ID: 31515083 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Koeberle D; Betticher DC; von Moos R; Dietrich D; Brauchli P; Baertschi D; Matter K; Winterhalder R; Borner M; Anchisi S; Moosmann P; Kollar A; Saletti P; Roth A; Frueh M; Kueng M; Popescu RA; Schacher S; Hess V; Herrmann R Ann Oncol; 2015 Apr; 26(4):709-714. PubMed ID: 25605741 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
20. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. Chen Y; Cao D; Bi F; Li Q; Qiu M Med Oncol; 2014 May; 31(5):935. PubMed ID: 24683007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]